Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Agenda
3. Proteomics: definition
4. Discovery of new markers
5. Proteomic utility in DN (Diabetic Nephropathy)
6. Albuminuria and mortality in DM individuals
7. RENAAL trial
8. Early intervention?
9. Natural history of diabetic nephropathy
10. U-albumin
11. Hypothesis driven search for new biomarkers
12. Growth differentiation factor 15
13. Multimarker proteomic techniques
14. Plasma proteomic analysis
15. Plasma proteome analysis of T1D patients
16. Network analysis on the case control ratio
17. Kininogen and kininogen fragments as markers
18. Erk 1/2 phosphorylation in tubular cell lines
19. CDK prediction post liver transplantation (1)
20. CDK prediction post liver transplantation (2)
21. Urine proteomic profiling
22. CE-MS proteomic technique
23. Proteomics technology platform
24. Individual analyses to compiled patterns
25. Individual analyses to compiled patterns: Example
26. Proteomic CKD biomarker discovery
27. CKD-biomarkers: collagen
28. CKD-biomarkers: apoptosis related proteins
29. Pathophysiological suggestions
30. Proteomic profile of T1DM with or without DN
31. Candesartan in T2DM and DN
32. Prediction analysis
33. Urinary protein profiles of ADPKD patients
34. Urinary proteomics in Fabry and controls
35. Profiles of ERT treated female Fabry patients
36. Marker implementation
37. Systems biology in CKD
38. Conclusions
39. Perspectives
40. Priority EU project
41. Priority EU project in details
42. Thank you for listening
43. Acknowledgements

Topics Covered

• Proteomics for clinical use
• Available and applied single risk marker strategies in nephrology based on hypothesis driven biomarker search
• Open or unbiased multimarker approaches including plasma and urine proteomics
• Examples from different renal diseases
• Data from cross sectional and longitudinal studies
• Proteomics may provide insight into disease pathology
• Proteomics may provide risk stratification for clinical trials
• Example: intervention trial for type 2 diabetic subjects with high risk urinary proteomic pattern

Links

Series:

• Clinical Proteomics
• The Kidney in Health and Disease

Categories:

• Biochemistry
• Cell Biology
• Clinical Practice
• Methods

Therapeutic Areas:

• Gastroenterology & Nephrology

Talk Citation

Rossing, P. (2013, November 5). Proteomics in kidney disease: clinical considerations [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 14, 2025, from https://doi.org/10.69645/XPCZ7201.
Export Citation (RIS)

Publication History

• Published on November 5, 2013
• Archived on March 30, 2023

Financial Disclosures

• Professor Rossing has received the following: Consultancy and/or speaking fees (to his institution) from Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, MSD, Novo Nordisk and Sanofi Aventis, Research grants from AstraZeneca Bayer and Novo Nordisk.